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Introduction
• Upper patellar tendinopathies remain often 
chronic and resistant to conservative 
treatment.
• New treatments are being developed.
• Platelets contain lots of growth factors.
PRP
• In vitro and animal experiments have 
demonstrated that PRP can stimulate the 
tendon healing process.





• algofunctional scores (IKDC and VISA-P)
• functional assessments (isokinetic and optojump)
• imagery (US and MRI)




• PRP obtained by apheresis system (COM.TEC, 
Fresenius).
• Site located by US.
• 6mL of PRP were injected without anaesthetic.
• 1 week after infiltration ➙ 6-week standardised 
sub-maximal eccentric reeducation.













• Pain felt decreased at each functional 
evaluation.
• No functional improvement.
• No improvement in the imagery.
Results
• Patients with best improvement ➙ younger (24.7 vs 
32.2 y.o.) 
• VAS ≤ 1
• significant increase of IKDC score (p=0.003)
• significant improvement of pain during isokinetic 
evaluation (p<0.05) and optojump (p=0.01)
• 70% return to sport (50% same level).
Discussion
• A local infiltration of PRP + submaximal 
eccentric reeducation ➙ improvement of 
symptoms of chronic upper patellar 
tendinopathies.
• No functional or imagery improvement 
observed.
Discussion
• No general agreement on the preparation and 
use of PRP.
• Apheresis system provides:
• «pure» PRP (without red and white cells)
• reproducible PRP from one patient to 
another (duration of platelet collect depended on 
anthropometric and biologic parameters of each patient)
• choice of PRP concentration
Conclusion
• PRP can be a treatment for resistant 
chronic tendinopathies.
• RCT are still needed.
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